Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

Avacta Group (AVCT)

Price 138.50p on 28-11-2023 at 18:25:06
Change -2.00p -1.43%
Buy 140.00p
Sell 137.00p
Buy / Sell AVCT Shares
Last Trade: Unknown 15,000.00 at 138.15p
Day's Volume: 1,025,187
Last Close: 138.00p
Open: 139.50p
Day's Range 138.00p - 138.00p
52wk Range: 89.10p - 187.50p
Market Capitalisation: £391m
VWAP: 138.14007p
Shares in Issue: 284m

Recent Trades History Avacta Group (AVCT)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 15,000 138.15p Ordinary
16:25:06 - 28-Nov-23
Unknown* 15,000 138.15p Ordinary
16:01:52 - 28-Nov-23
Unknown* 55,000 140.50p Ordinary
08:01:01 - 27-Nov-23
Unknown* 210,348 140.00p Ordinary
16:10:36 - 27-Nov-23
Unknown* 25,000 140.215p Ordinary
11:21:43 - 27-Nov-23
Unknown* 100,000 140.65p Ordinary
08:13:09 - 27-Nov-23
Unknown* 25,000 140.15p Ordinary
11:47:34 - 27-Nov-23
Unknown* 50,000 140.25p Ordinary
12:41:24 - 27-Nov-23
Unknown* 25,000 140.515p Ordinary
10:11:14 - 27-Nov-23
Unknown* 207 138.007p Ordinary
Currency Conversion
OTC Trade
16:56:50 - 28-Nov-23

Share Price History for Avacta Group

Time period:
Date Open High Low Close Volume

Share News for Avacta Group

IN BRIEF: Avacta loss widens on cost rise but clinical tests positive

28th Sep 2023 11:08

Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter. Read More

UK earnings, trading statements calendar - next 7 days

21st Sep 2023 15:48

Read More

TRADING UPDATES: Capital inks contract; Lansdowne becomes cash shell

20th Sep 2023 14:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

Avacta notes "excellent" safety profile for prospective sarcoma drug

19th Sep 2023 13:36

(Alliance News) - Avacta Group PLC on Tuesday said it successfully completed the sixth dose escalation of the ALS-6000-101 phase 1 clinical trial, in which its AVA6000 soft tissue sarcoma treatment demonstrated an "excellent" safety profile. Read More

IN BRIEF: Avacta Group issues 3.8 million shares to make repayment

21st Jul 2023 16:00

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Issues 3.8 million new shares of 10 pence each to settle quarterly principal of GBP2.6 million and interest repayment of GBP760,000. After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by GBP2.6 million to GBP44.2 million. Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered